| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10925871 | ZYDUS | Pharmaceutical compositions of sitagliptin |
Feb, 2035
(10 years from now) | |
Zituvio is owned by Zydus.
Zituvio contains Sitagliptin.
Zituvio has a total of 1 drug patent out of which 0 drug patents have expired.
Zituvio was authorised for market use on 18 October, 2023.
Zituvio is available in tablet;oral dosage forms.
The generics of Zituvio are possible to be released after 25 February, 2035.
Drugs and Companies using SITAGLIPTIN ingredient
Market Authorisation Date: 18 October, 2023
Treatment: NA
Dosage: TABLET;ORAL
More Information on Dosage
ZITUVIO family patents
